Access & Support

Fully digital. End-to-end support.

Make every step of prescribing and treatment with reSET and reSET-O faster and simpler with PearConnect, a support center built to fit seamlessly into your existing practice workflows.

With PearConnect™, you’ll get access to a dedicated case manager to support your practice at every step along the patient recovery journey. We can help:

  • Facilitate patient access to reSET® or reSET-O® and answer questions
  • Assist with payer coverage determination on behalf of your patients
  • Assist you or your staff with general questions around ICD-10 diagnosis codes and CPT codes

For patients and their caregivers, we built a fully digital experience designed to make onboarding and access fast, easy, and stress-free.

  • Deliver personalized onboarding guidance, product education, therapy initiation and adherence, and technical support
  • Provide benefits investigation services and help determine copay assistance eligibility (eligible patients pay no more than $15 out of pocket for each prescription)
  • Provide information and support for access to the PEAR Assistance Program when appropriate

Contact us

Call: 1-833-697-3738

Fax: 1-877-256-1320

Hours: 8 am-8 pm (ET) Mon-Fri

PEAR Assistance Program

Expanding access through the PEAR Assistance Program

This program ensures eligible patients have access to FDA-authorized prescription digital therapeutics for addiction treatment. The program provides access to reSET or reSET-O, free of charge, to qualifying patients who are currently under the supervision of a licensed US healthcare provider on an outpatient basis.

Please call us at 1-833-697-3738 for more information.

how to prescribe

Digital prescribing options

Prescribing can be done through the PearConnect clinician-facing prescribing portal, electronic prescription (eRx) from your own EHR system, or PDF enrollment form.

We provide 3 simple ways to prescribe reSET and reSET-O. Whichever option you choose, your patient will be contacted by PearConnect, who will obtain their consent and onboard them via text.

  1. Write remote prescriptions. 
  2. See where patients are in their onboarding process from when the prescription is written to when it is filled.
  3. See outstanding actions your practice needs to take to complete the prescribing process.

Once in your eRx tool:

  1. Enter the NCPDP number “5660091.” (Pharmacy name will appear as “Postmeds, Inc” or “Truepill.”†) 3121 Diablo Ave, Hayward, CA 94545 | NPI: 1295182590 | Phone: 1-650-353-5495
  2. Select “reSET” or “reSET-O” as the prescription.
  3. Ensure all required fields are complete before submitting.
  4. In Notes section:
    • Indicate contingency management (CM) (enter “CM Virtual Rewards” or “CM Monetary Rewards”)
    • Indicate whether patient is on buprenorphine (enter “Buprenorphine”)

*Requires current compendia, as of 2019.
†Truepill is a third-party pharmacy.

  1. Complete an editable PDF Enrollment Form below. Be sure to include a phone number for a direct contact who can confirm daily prescriptions.
  2. Email the completed Enrollment Form to PearConnect@PearTherapeutics.com.
  3. The PearConnect Patient Service Center will reach out to you or your office staff via phone once a day to confirm the prescriptions for your patients.

Download Enrollment Form

Interested in prescribing reSET or reSET-O?

reSET® Indications for Use:

reSET is intended to provide cognitive behavioral therapy, as an adjunct to a contingency management system, for patients 18 years of age and older, who are currently enrolled in outpatient treatment under the supervision of a clinician. reSET is indicated as a 12-week (90 day) prescription-only treatment for patients with substance use disorder (SUD), who are not currently on opioid replacement therapy, who do not abuse alcohol solely, or who do not abuse opioids as their primary substance of abuse.

It is intended to:
  • increase abstinence from a patient’s substances of abuse during treatment, and
  • increase retention in the outpatient treatment program.

reSET® Important Safety Information for Clinicians:

Warnings: reSET is intended for patients whose primary language is English with a reading level of 7th grade or above, and who have access to an Android/iOS tablet or smartphone. reSET is intended only for patients who own a smartphone and are familiar with use of smartphone apps (applications).

Clinicians should not use reSET to communicate with their patients about emergency medical issues. Patients should be clearly instructed not to use reSET to communicate to their clinician any urgent or emergent information. In case of an emergency, patients should dial 911 or go to the nearest emergency room

reSET is not intended to be used as a stand-alone therapy for substance use disorder (SUD). reSET does not replace care by a licensed medical practitioner and is not intended to reduce the amount of face-to-face clinician time. reSET does not represent a substitution for a patient’s medication. Patients should continue to take their medications as directed by their healthcare provider.

Patients with substance use disorder experience mental health disease and co-morbid medical problems at higher rates than the general population. Patients with substance use disorder also have higher baseline rates of suicidal ideation, and suicide attempts, and suicide completion. Clinicians should engage in their normal care practices to monitor patients for medical problems and mental health disorders, including risk for harming others and/or themselves.

The long-term benefit of treatment with reSET on abstinence has not been evaluated in studies lasting beyond 12 weeks (90 days) in the SUD population. The ability of reSET to prevent potential relapse after treatment discontinuation has not been studied.

The effectiveness of reSET has not been demonstrated in patients currently reporting opioids as their primary substance of abuse.

Please see the Clinician Brief Summary Instructions for reSET.

reSET-O® Indications for Use:

reSET-O prescription digital therapeutic is a 12-week (84 day) software application intended to increase retention of patients with opioid use disorder (OUD) in outpatient treatment by providing cognitive behavioral therapy, as an adjunct to outpatient treatment that includes transmucosal buprenorphine and contingency management, for patients 18 years or older who are currently under the supervision of a clinician. reSET-O is indicated as a prescription-only digital therapeutic.

reSET-O® Important Safety Information for Clinicians:

Warnings: reSET-O is intended for patients whose primary language is English with a reading level of 7th grade or above, and who have access to an Android/iOS tablet or smartphone. reSET-O is intended only for patients who own a smartphone and are familiar with use of smartphone apps (applications). Clinicians should not use reSET-O to communicate with their patients about emergency medical issues. Patients should be clearly instructed not to use reSET-O to communicate to their clinician any urgent or emergent information. In case of an emergency, patients should dial 911 or go to the nearest emergency room.

reSET-O is not intended to be used as a stand-alone therapy for Opioid Use Disorder (OUD). reSET-O does not replace care by a licensed medical practitioner and is not intended to reduce the frequency or duration of in-person therapy. reSET-O does not represent a substitution for a patient’s medication. Patients should continue to take their medications as directed by their healthcare provider.

Patients with opioid use disorder experience mental health disease and co-morbid medical problems at higher rates than the general population. Patients with opioid use disorder have higher baseline rates of suicidal ideation, and suicide attempts, and suicide completion. Clinicians should undertake standard of care to monitor patients for medical problems and mental health disease, including risk for harming others and/or themselves.

The long-term benefit of reSET-O has not been evaluated in studies lasting beyond 12 weeks (84 days) in the OUD population. The ability of reSET-O to prevent potential relapse after therapy discontinuation has not been studied.

Please see the Clinician Brief Summary Instructions for reSET-O.
This information is intended for US healthcare professionals. Please confirm you are a healthcare professional to continue.